Cancer Cytogenetics

Edited by
Sverre Heim
Felix Mitelman

Chromosomal and Molecular Genetic Aberrations of Tumor Cells

WILEY Blackwell

Cancer Cytogenetics

Cancer Cytogenetics

Chromosomal and Molecular Genetic Aberrations of Tumor Cells

Fourth Edition

EDITED BY

Sverre Heim

Section for Cancer Cytogenetics
Institute for Cancer Genetics and Informatics
Oslo University Hospital
Oslo, Norway

Felix Mitelman

Department of Clinical Genetics
University of Lund
Lund, Sweden

WILEY Blackwell

This edition first published 2015 © 2015 by John Wiley & Sons, Ltd.
Third edition published 2009 © 2009 by John Wiley & Sons, Inc.

Registered Office
John Wiley & Sons, Ltd, The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK

Editorial Offices
9600 Garsington Road, Oxford, OX4 2DQ, UK
The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK
111 River Street, Hoboken, NJ 07030-5774, USA

For details of our global editorial offices, for customer services and for information about how to apply for permission to reuse the copyright material in this book please see our website at www.wiley.com/wiley-blackwell

The right of the author to be identified as the author of this work has been asserted in accordance with the UK Copyright, Designs and Patents Act 1988.

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, except as permitted by the UK Copyright, Designs and Patents Act 1988, without the prior permission of the publisher.

Designations used by companies to distinguish their products are often claimed as trademarks. All brand names and product names used in this book are trade names, service marks, trademarks or registered trademarks of their respective owners. The publisher is not associated with any product or vendor mentioned in this book. It is sold on the understanding that the publisher is not engaged in rendering professional services. If professional advice or other expert assistance is required, the services of a competent professional should be sought.

The contents of this work are intended to further general scientific research, understanding, and discussion only and are not intended and should not be relied upon as recommending or promoting a specific method, diagnosis, or treatment by health science practitioners for any particular patient. The publisher and the author make no representations or warranties with respect to the accuracy or completeness of the contents of this work and specifically disclaim all warranties, including without limitation any implied warranties of fitness for a particular purpose. In view of ongoing research, equipment modifications, changes in governmental regulations, and the constant flow of information relating to the use of medicines, equipment, and devices, the reader is urged to review and evaluate the information provided in the package insert or instructions for each medicine, equipment, or device for, among other things, any changes in the instructions or indication of usage and for added warnings and precautions. Readers should consult with a specialist where appropriate. The fact that an organization or Website is referred to in this work as a citation and/or a potential source of further information does not mean that the author or the publisher endorses the information the organization or Website may provide or recommendations it may make. Further, readers should be aware that Internet Websites listed in this work may have changed or disappeared between when this work was written and when it is read. No warranty may be created or extended by any promotional statements for this work. Neither the publisher nor the author shall be liable for any damages arising herefrom.

Library of Congress Cataloging-in-Publication Data

Cancer cytogenetics (Heim)
Cancer cytogenetics : chromosomal and molecular genetic aberrations of tumor cells / edited by Sverre Heim, Felix Mitelman. – Fourth edition.
p. ; cm.
Includes bibliographical references and index.
ISBN 978-1-118-79553-8 (cloth)
I. Heim, Sverre, editor. II. Mitelman, Felix, editor. III. Title.
[DNLM: 1. Neoplasms–genetics. 2. Chromosome Disorders–genetics. 3. Cytogenetics–methods. QZ 202]
RC268.4
616.99′4042–dc23

2015015465

A catalogue record for this book is available from the British Library.

Wiley also publishes its books in a variety of electronic formats. Some content that appears in print may not be available in electronic books.

Set in 9.5/12pt Minion by SPi Global, Pondicherry, India

1 2015

Contents

Contributors, vii

Preface to the Fourth Edition, ix

1 How it all began: cancer cytogenetics before sequencing, 1
Felix Mitelman and Sverre Heim

2 Cytogenetic methods, 11
David Gisselsson

3 Cytogenetic nomenclature, 19
Sverre Heim and Felix Mitelman

4 Nonrandom chromosome abnormalities in cancer: an overview, 26
Sverre Heim and Felix Mitelman

5 From chromosomes to genes: searching for pathogenetic fusions in cancer, 42
Ioannis Panagopoulos

6 Acute myeloid leukemia, 62
Bertil Johansson and Christine J. Harrison

7 Myelodysplastic syndromes, 126
Harold J. Olney and Michelle M. Le Beau

8 Chronic myeloid leukemia, 153
Thoas Fioretos

9 Chronic myeloproliferative neoplasms, 175
Peter Vandenberghe and Lucienne Michaux

10 Acute lymphoblastic leukemia, 198
Christine J. Harrison and Bertil Johansson

11 Mature B- and T-cell neoplasms and Hodgkin lymphoma, 252
Reiner Siebert and Sietse M. Aukema

12 Tumors of the upper aerodigestive tract, 332
Susanne M. Gollin

13 Tumors of the lung, 361
Penny Nymark, Eeva Kettunen and Sakari Knuutila

14 Tumors of the digestive tract, 373
Georgia Bardi and Sverre Heim

15 Tumors of the urinary tract, 401
Paola Dal Cin

16 Tumors of the breast, 426
Manuel R. Teixeira, Nikos Pandis and Sverre Heim

17 Tumors of the female genital organs, 447
Francesca Micci and Sverre Heim

18 Tumors of the male genital organs, 481
Manuel R. Teixeira and Sverre Heim

19 Tumors of endocrine glands, 497
Jörn Bullerdiek and David Gisselsson

20 Tumors of the nervous system, 515
Petter Brandal and Sverre Heim

21 Tumors of the eye, 538
Karen Sisley

22 Tumors of the skin, 555
Fredrik Mertens, Felix Mitelman and Sverre Heim

23 Tumors of bone, 566
Fredrik Mertens and Nils Mandahl

24 Soft tissue tumors, 583
Nils Mandahl and Fredrik Mertens

Index, 615

Contributors

Sietse M. Aukema
Institute of Human Genetics
University Hospital Schleswig-Holstein Campus Kiel
Christian-Albrechts University Kiel
Germany

Georgia Bardi
BioAnalytica-GenoType SA
Molecular Cytogenetic Research and Applications
Athens, Greece

Petter Brandal
Section for Cancer Cytogenetics
Institute for Cancer Genetics and Informatics
Olso University Hospital
Oslo, Norway

Jörn Bullerdiek
Center for Human Genetics
University of Bremen
Bremen, Germany

Paola Dal Cin
Department of Pathology
Brigham and Women's Hospital
Boston, MA, USA

Thoas Fioretos
Department of Clinical Genetics
University of Lund
Lund, Sweden

David Gisselsson
Department of Clinical Genetics
University of Lund
Lund, Sweden

Susanne M. Gollin
Department of Human Genetics
University of Pittsburgh Graduate School of Public Health
University of Pittsburgh Cancer Institute
Pittsburgh, PA, USA

Christine J. Harrison
Leukaemia Research Cytogenetics Group
Northern Institute for Cancer Research
Newcastle University
Newcastle upon Tyne, UK

Sverre Heim
Section for Cancer Cytogenetics
Institute for Cancer Genetics and Informatics
Olso University Hospital
Oslo, Norway

Bertil Johansson
Department of Clinical Genetics
University of Lund
Lund, Sweden

Eeva Kettunen
Health and Work Ability
Systems Toxicology
Finnish Institute of Occupational Health
Helsinki, Finland

Sakari Knuutila
Department of Pathology
Haartman Institute and HUSLAB
University of Helsinki and Helsinki University Central Hospital
Helsinki, Finland

Michelle M. Le Beau
Section of Hematology/Oncology
University of Chicago
Chicago, IL, USA

Nils Mandahl
Department of Clinical Genetics
University of Lund
Lund, Sweden

Fredrik Mertens
Department of Clinical Genetics
University of Lund
Lund, Sweden

Francesca Micci
Section for Cancer Cytogenetics
Institute for Cancer Genetics and Informatics
Olso University Hospital
Oslo, Norway

Lucienne Michaux
Centre for Human Genetics
University Hospitals Leuven
University of Leuven
Leuven, Belgium

Felix Mitelman
Department of Clinical Genetics
University of Lund
Lund, Sweden

Penny Nymark
Department of Toxicogenomics
Maastricht University
Maastricht, The Netherlands;
Institute of Environmental Medicine
Karolinska Institute
Stockholm, Sweden

Harold J. Olney
Centre Hospitalier de l'Universitié
de Montréal (CHUM)
Université de Montréal
Montréal, Quebec, Canada

Ioannis Panagopoulos
Section for Cancer Cytogenetics
Institute for Cancer Genetics and
Informatics
Olso University Hospital
Oslo, Norway

Nikos Pandis
Department of Genetics
Saint Savas Hospital
Athens, Greece

Reiner Siebert
Institute of Human Genetics
University Hospital Schleswig-
Holstein Campus Kiel
Christian-Albrechts University Kiel
Germany

Karen Sisley
Academic Unit of Ophthalmology
and Orthoptics
Department of Oncology
The Medical School
University of Sheffield
Sheffield, UK

Manuel R. Teixeira
Department of Genetics
Portuguese Oncology Institute
Porto, Portugal

Peter Vandenberghe
Centre for Human Genetics
University Hospitals Leuven
University of Leuven
Leuven, Belgium

Preface to the Fourth Edition

Although only six years have passed since the publication of the third edition of *Cancer Cytogenetics*, the field has undergone marked changes. New information about many tumor types has been gathered using chromosome banding and various molecular cytogenetic techniques, but first and foremost it is the increasing addition of state-of-the-art genomic analyses to the chromosome-level studies of neoplastic cells that has now brought about a more detailed and better understanding of how neoplastic transformation occurs in different disease entities. Inevitably, therefore, this fourth edition contains a wider coverage of the molecular genetic changes that neoplastic cells have acquired than was possible in previous editions. The main focus nevertheless remains unaltered: the genomic aberrations of neoplastic cells as they appear at the chromosomal level of organization. To put the molecular knowledge and studies—especially those involving various ways to search for pathogenetic fusion genes by means of whole genome sequencing—into an integrated molecular genetic–cytogenetic perspective, an entire new chapter was added. Otherwise the overall structure of the book remains the same as it was in the previous edition: the first five chapters, Chapters 1–5, are more generic in nature, Chapters 6–11 deal with hematologic malignancies and lymphomas, and Chapters 12–24 review existing cytogenetic and molecular genetic knowledge on solid tumors.

In all the chapters of this edition, we have strived to emphasize the clinical impact of the various acquired rearrangements, be it diagnostic or prognostic, as much as possible. Cancer cytogenetics has come of age as one of the several means whereby different neoplastic diseases could and should be diagnosed—especially hematologic disorders, malignant lymphomas, and tumors of bone and soft tissue but also increasingly other solid tumors—and it is imperative that cancer cytogeneticists communicate these aspects of their work to the pathologists and clinicians who are in direct charge of the patients. The closer the dialogue with other diagnosticians and clinicians, the more useful the karyotype and other cytogenetic and molecular findings will be in the risk assessment and choice of therapy for individual patients.

At the same time, cancer cytogenetics remains pivotal in the examination of neoplastic cells for research purposes. Chromosome banding analysis is a robust and unbiased method whereby global genetic information can be obtained at the cytogenetic level. All molecular examinations of tumor cells should ideally be viewed against the background of knowledge about the tumor karyotype.

A large number of experts have helped us write the various chapters of *Cancer Cytogenetics*, Fourth Edition. They have done a better job than we ever could even if we had had unlimited time on our hands, and we are profoundly grateful to all of them. The heterogeneity inevitable resulting from multiple authorship reflects reality within the scientific community and we choose to see it as an advantage rather than a disadvantage. We have nevertheless strived to impart a recognizable common format on the various organ-specific chapters so as to comply with the overall plan of the book. It is our hope that those who read and use this book will agree with us that the final result does the field of cancer cytogenetics the credit that is its due.

Sverre Heim
Felix Mitelman
Oslo and Lund, December 2014

1

CHAPTER 1

How it all began: cancer cytogenetics before sequencing

Felix Mitelman[1] *and Sverre Heim*[2]

[1] Department of Clinical Genetics, University of Lund, Lund, Sweden
[2] Section for Cancer Cytogenetics, Institute for Cancer Genetics and Informatics, Oslo University Hospital, Oslo, Norway

The role of genetic changes in neoplasia has been a matter of debate for more than 100 years. The earliest systematic study of cell division in malignant tumors was made in 1890 by the German pathologist David von Hansemann. He drew attention to the frequent occurrence of aberrant mitoses in carcinoma biopsies and suggested that this phenomenon could be used as a criterion for diagnosing the malignant state. His investigations as well as other studies associating nuclear abnormalities with neoplastic growth were, a quarter of a century later, forged into a systematic somatic mutation theory of cancer, which was presented in 1914 by Theodor Boveri in his famous book *Zur Frage der Entstehung maligner Tumoren*. According to Boveri's hypothesis, chromosome abnormalities were the cellular changes causing the transition from normal to malignant proliferation.

For a long time, Boveri's remarkably prescient idea, the concept that neoplasia is brought about by an acquired genetic change, could not be tested. The study of sectioned material yielded only inconclusive results and was clearly insufficient for the examination of chromosome morphology. Technical difficulties thus prevented reliable visualization of mammalian chromosomes, in both normal and neoplastic cells, throughout the entire first half of the 20th century.

During these "dark ages" of mammalian cytogenetics (Hsu, 1979), plant cytogeneticists made spectacular progress, very much through their use of squash and smear preparations. These techniques had from 1920 onward greatly facilitated studies of the genetic material in plants and insects, disclosing chromosome structures more reliably and with greater clarity than had been possible in tissue sections. Around 1950, it was discovered that some experimental tumors in mammals, in particular the Ehrlich ascites tumor of the mouse, could also be examined using the same squash and smear approach. These methods were then rapidly tried with other tissues as well, and in general, mammalian chromosomes were found to be just as amenable to detailed analysis as the most suitable plant materials.

Simultaneously, tissue culturing became more widespread and successful, one effect of which was that the cytogeneticists now had at their disposal a stable source of *in vitro* grown cells. Of crucial importance in this context was also the discovery that colchicine pretreatment resulted in mitotic arrest and dissolution of the spindle apparatus and that treatment of arrested cells with a hypotonic salt solution greatly improved the quality of metaphase spreads. Individual chromosomes could now be counted and analyzed. The many

Cancer Cytogenetics: Chromosomal and Molecular Genetic Aberrations of Tumor Cells, Fourth Edition.
Edited by Sverre Heim and Felix Mitelman.
© 2015 John Wiley & Sons, Ltd. Published 2015 by John Wiley & Sons, Ltd.

Figure 1.1 Camera lucida drawing of tumor cell mitosis from one of the first (early 1950s) human cancerous effusions submitted to detailed chromosome analysis. The modal number was 75. The stemline also contained numerous abnormal chromosome shapes (Courtesy of Prof. Albert Levan).

methodological improvements ushered in a period of vivid expansion in mammalian cytogenetics, culminating in the description of the correct chromosome number of man by Tjio and Levan (1956) and, shortly afterward, the discovery of the major constitutional human chromosomal syndromes. Two technical breakthroughs around the turn of the decade were of particular importance: the finding that phytohemagglutinin (PHA) has a mitogenic effect on lymphocytes (Nowell, 1960) and the development of a reliable method for short-term culturing of peripheral blood cells (Moorhead et al., 1960).

Cytogenetic studies of animal ascites tumors during the early 1950s, followed soon by investigations of malignant exudates in humans (Figure 1.1), uncovered many of the general principles of karyotypic patterns in highly advanced, malignant cell populations: the apparently ubiquitous chromosomal variability within the tumor, surmised by pathologists since the 1890s; the stemline concept, first defined by Winge (1930); and the competition between stemlines resulting in labile chromosomal equilibria responsive to environmental alterations. The behavior of malignant cell populations could now be described in Darwinian terms: by selective pressures, a dynamic equilibrium is maintained, but any environmental change may upset the balance, causing shifts of the stemline karyotype. Evolution thus occurs in tumor cell populations in much the same manner as in populations of organisms: chromosomal aberrations generate genetic diversity, and the relative "fitness" imparted by the various changes decides which subclones will prevail.

The elucidation of these evolutionary principles in numerous studies by a number of investigators, for example, Hauschka (1953), Levan (1956), and Makino (1956), paved the way for the new and growing understanding of the role of karyotypic changes in neoplasia and laid the foundation of modern cancer cytogenetics. In humans as well as in other mammals, the results strongly indicated that the chromosomal abnormalities observed were an integral part of tumor development and evolution (see, e.g., Levan, 1967; Koller, 1972; Hsu, 1979; Sandberg, 1980, for review of the early data). It should be kept in mind, however, that the object of these early investigations was always metastatic tumors, often effusions, that is, highly malignant cell populations. Hence, few, if any, conclusions could be drawn from them as to the role of chromosomal abnormalities in early tumor stages.

Interest in cancer cytogenetics influenced human cytogenetics much more profoundly than is currently appreciated. For example, the main goal behind the study that eventually led to the description of the correct chromosome number in man (Tjio and Levan, 1956) was to identify what distinguished a cancer cell. The motivation was not primarily an interest in the normal chromosome constitution, which at that time had no obvious implications, but the hope that such knowledge would help answer the basic question of whether chromosome changes lay behind the transformation of a normal to a cancer cell.

The first spectacular success in cancer cytogenetics came when Nowell and Hungerford (1960) discovered that a small karyotypic marker (Figure 1.2), the Philadelphia (Ph) chromosome, replaced one of the four smallest autosomes (the G-group chromosomes according to the nomenclature at the time) in the bone marrow cells of seven patients with chronic myeloid leukemia (CML). This was the first consistent chromosome abnormality in a human cancer, and its detection seemed to provide conclusive verification of Boveri's idea. It was reasonable to assume that the acquired chromosomal abnormality—a perfect example of a somatic



Figure 1.2 Unbanded metaphase cell from a bone marrow culture established from a patient with chronic myeloid leukemia. The arrow indicates the Ph chromosome (previously called Ph[1]); the superscript indicated that this was the first cancer-specific aberration detected in Philadelphia. This naming practice was later abandoned, but the abbreviation Ph has for sentimental reasons been retained, since it was the first consistent chromosome abnormality detected in a human malignancy.

mutation in a hematopoietic stem cell—was the direct cause of the neoplastic state.

Nowell and Hungerford's discovery greatly stimulated interest in cancer cytogenetics in the early 1960s, but for several reasons, the Ph chromosome long remained an exceptional finding. The confusing plethora of karyotypic aberrations encountered in other malignancies suggested that the changes were epiphenomena incurred during tumor progression rather than essential early pathogenetic factors. The enthusiasm for tumor cytogenetics as a result gradually faded. With this change of mood, the perceived significance of the Ph chromosome also changed, and the very uniqueness of the marker came to be regarded as a perplexing oddity. Why should there be such a simple association between a chromosomal trait and one particular malignant disease, when more and more data from other neoplasms showed either no chromosome aberrations at all or a confusing mixture of apparently meaningless abnormalities?

That an orderly pattern existed in what had hitherto been seen as chaos was suggested independently in the mid-1960s by Levan (1966) and van Steenis (1966). Surveying chromosomal data available in the literature, mainly on ascitic forms of gastric, mammary, uterine, and ovarian carcinomas, they found clear evidence that certain chromosome types tended to increase and others to decrease in number in the tumors. Soon afterward, the nonrandomness of karyotypic changes was also demonstrated beyond doubt in specific types of human hematologic disorders and solid tumors; for example, trisomy of a C chromosome in acute myeloid leukemia (Hungerford and Nowell, 1962), deletion of an F-group chromosome in polycythemia vera (Kay et al., 1966), loss of a G chromosome in meningioma (Zang and Singer, 1967), and a C–G translocation in acute myeloid leukemia (Kamada et al., 1968). The results of comprehensive cytogenetic studies of experimental tumors, including more than 200 primary sarcomas induced by the Rous sarcoma virus in mice, rats, and the Chinese hamster, supported the same conclusion (Mitelman, 1974). In both humans and animals, the karyotypic abnormalities seemed to be of two essentially different kinds: nonrandom changes preferentially involving particular chromosomes and a frequently more massive random or background variation affecting all chromosomes. To differentiate between the two could be exceedingly difficult, however. As a consequence, in spite of painstaking efforts, little progress was made in cancer cytogenetics during this period.

The situation changed dramatically in 1970 with the introduction by Caspersson and Zech of chromosome banding techniques (Caspersson et al., 1970a). The new methodology completely revolutionized cytogenetic analyses. Each chromosome could now be precisely identified on the basis of its unique banding pattern; whereas formerly identification was restricted to chromosome groups, all descriptions of chromosome deviations immediately became more precise and the conclusions based on them more stringent. As a consequence, a steadily increasing number of cancer cases, initially predominantly malignant hematologic disorders, were investigated with the new techniques, and a number of characteristic, specific, sometimes even pathognomonic changes were soon discovered (Table 1.1). Caspersson et al. (1970b) first used banding in this context and identified the Ph chromosome as a deleted chromosome 22, and in 1972, three of the nonrandom aberrations described in the 1960s were clarified: the additional C-group

Table 1.1 Characteristic neoplasia-associated cytogenetic aberrations detected by banding analyses 1970–1979

Year	*Disease*	*Aberration*	*References*
1970	Chronic myeloid leukemia	del(22q)	Caspersson et al. (1970b)
1972	Acute myeloid leukemia	+8	de la Chapelle et al. (1972)
	Burkitt lymphoma	14q+	Manolov and Manolova (1972)
	Meningioma	−22	Mark et al. (1972) and Zankl and Zang (1972)
	Polycythemia vera	del(20q)	Reeves et al. (1972)
1973	Acute myeloid leukemia	t(8;21)(q22;q22)	Rowley (1973a)
	Acute myeloid leukemia	i(17)(q10)	Mitelman et al. (1973)
	Acute myeloid leukemia	−7/del(7q)	Petit et al. (1973) and Rowley (1973c)
	Chronic myeloid leukemia	t(9;22)(q34;q11)	Rowley (1973b)
	Acute myeloid leukemia/ Myeloproliferative disorders	+9	Davidson and Knight (1973), Rowley (1973d), and Rutten et al. (1973)
1974	Acute myeloid leukemia	+21	Mitelman and Brandt (1974)
	Refractory anemia	del (5q)	van den Berghe et al. (1974)
1975	Myeloproliferative disease	t(11;20)(p15;q11)	Berger (1975)
1976	Acute myeloid leukemia	t(6;9)(p23;q34)	Rowley and Potter (1976)
	Burkitt lymphoma	t(8;14)(q24;q32)	Zech et al. (1976)
1977	Acute lymphoblastic leukemia	t(4;11)(q21;q23)	Oshimura et al. (1977)
	Acute promyelocytic leukemia	t(15;17)(q22;q21)	Rowley et al. (1977)
	Neuroblastoma	del(1p)	Brodeur et al. (1977)
1978	Acute monocytic leukemia	t(8;16)(p11;p13)	Mitelman et al. (1978)
	Acute myeloid leukemia	ins(3;3)(q21;q21q26)	Golomb et al. (1978)
1979	Acute lymphoblastic leukemia	t(8;14)(q24;q32)	Berger et al. (1979a) and Mitelman et al. (1979)
	Burkitt lymphoma	t(2;8)(p12;q24)	Miyoshi et al. (1979) and van den Berghe et al. (1979)
	Burkitt lymphoma	t(8;22)(q24;q11)	Berger et al. (1979b)
	Chronic lymphocytic leukemia	+12	Autio et al. (1979)
	Follicular lymphoma	t(14;18)(q32;q21)	Fukuhara et al. (1979)
	Mouse plasmacytoma	t(6;15), t(12;15)	Ohno et al. (1979)

chromosome in acute myeloid leukemia was identified as trisomy 8 (de la Chapelle et al., 1972), the lost G-group chromosome in meningioma corresponded to monosomy 22 (Mark et al., 1972; Zankl and Zang, 1972), and the deleted F-group chromosome in polycythemia vera was a del(20q) (Reeves et al., 1972). A previously unrecognized recurrent abnormality, a 14q + marker chromosome in Burkitt lymphoma (BL), was also described the very same year (Manolov and Manolova, 1972). The first recurrent balanced rearrangements were reported shortly afterward: a reciprocal translocation between chromosomes 8 and 21, that is, t(8;21)(q22;q22), was found in the bone marrow cells of some patients with acute myeloid leukemia (Rowley, 1973a), and the Ph chromosome of CML was demonstrated to stem from a t(9;22)(q34;q11), not a deletion of chromosome 22 as was previously thought (Rowley, 1973b). Among other important translocations also soon identified were t(8;14)(q24;q32), t(2;8)(p12;q34), and t(8;22)(q24;q11) in BL (Zech et al., 1976; Berger et al., 1979b; Miyoshi et al., 1979; van den Berghe et al., 1979), t(15;17)(q22;q21) in acute promyelocytic leukemia (Rowley et al., 1977), t(4;11)(q21;q23) in acute lymphoblastic leukemia (Oshimura et al., 1977), and t(14;18)(q32;q21) in follicular lymphoma (Fukuhara et al., 1979). Ohno et al. (1979) identified two characteristic translocations—t(6;15) and t(12;15)—in mouse plasmacytomas (MPC), the first specific rearrangements in experimental neoplasms and, as it turned out (see below), the perfect equivalents of the characteristic translocations in human BL. In total, more than 1200 neoplasms with clonal abnormalities were reported during this first decade of banding cytogenetics,

Table 1.2 Characteristic cytogenetic aberrations detected by banding analyses of solid tumors 1980–1989

Year	*Tumor type*	*Aberration*	*References*
1980	Salivary gland adenoma	t(3;8)(p21;q12)	Mark et al. (1980)
1982	Germ cell tumors	i(12)(p10)	Atkin and Baker (1982)
	Lung cancer	del(3)(p14p23)	Whang-Peng et al. (1982)
	Retinoblastoma	i(6)(p10)/del(13q)	Balaban et al. (1982) and Kusnetsova et al. (1982)
	Rhabdomyosarcoma (alveolar)	t(2;13)(q36;q14)	Seidal et al. (1982)
1983	Ewing sarcoma	t(11;22)(q24;q12)	Aurias et al. (1983) and Turc-Carel et al. (1983)
	Salivary gland adenoma	der(12)(q13–15)	Stenman and Mark (1983)
	Wilms' tumor	der(16)t(1;16)(q21;q13)	Kaneko et al. (1983)
1985	Chondrosarcoma (myxoid)	t(9;22)(q31;q12)	Hinrichs et al. (1985)
1986	Kidney cancer	t(X;1)(p11;q21)	de Jong et al. (1986)
	Lipoma	t(3;12)(q27;q13)	Heim et al. (1986) and Turc-Carel et al. (1986)
	Liposarcoma (myxoid)	t(12;16)(q13;p11)	Limon et al. (1986a)
	Salivary gland carcinoma	t(6;9)(q23;p23)	Stenman et al. (1986)
	Synovial sarcoma	t(X;18)(p11;q11)	Limon et al. (1986b)
1987	Kidney cancer	del(3p)/der(3)t(3;5)(p13;q22)	Kovacs et al. (1987)
	Lipoma	Ring chromosome(s)	Heim et al. (1987)
	Lipoma	der(12)(q13–15)	Mandahl et al. (1987)
1988	Primitive neuroectodermal tumor	i(17)(q10)	Griffin et al. (1988)
	Salivary gland cystadenolymphoma	t(11;19)(q21;p13)	Bullerdiek et al. (1988)
	Uterine leiomyoma	del(7)(q22q31)	Boghosian et al. (1988)
	Uterine leiomyoma	t(12;14)(q14;q24)	Heim et al. (1988), Mark et al. (1988), and Turc-Carel et al. (1988)
1989	Infantile fibrosarcoma	+8,+11,+20	Mandahl et al. (1989) and Speleman et al. (1989)
	Lipoma	der(6)(p21)	Sait et al. (1989)
	Ovarian cancer	add(19)(p13)	Pejovic et al. (1989)

and more than 60 recurrent chromosomal aberrations were identified.

The following decade saw a rush of data coming from studies of solid tumors, initially in particular mesenchymal neoplasms. The chromosome abnormalities of more than 2000 solid tumors were reported between 1980 and 1989, and almost 200 recurrent structural changes were identified. Several of them were no less specific than those previously found among hematologic disorders (Table 1.2), for example, t(2;13)(q36;q14) in alveolar rhabdomyosarcoma (Seidal et al., 1982), t(11;22)(q24;q12) in Ewing sarcoma (Aurias et al., 1983; Turc-Carel et al., 1983), and t(12;16)(q13;p11) in myxoid liposarcoma (Limon et al., 1986a). At this time, it also became clear that many benign tumors carried characteristic aberrations, including reciprocal translocations, for example, t(3;8)(p21;q12) in salivary gland adenoma (Mark et al., 1980), t(3;12)(q27;q13) in lipoma (Heim et al., 1986; Turc-Carel et al., 1986), and t(12;14)(q14;q24) in uterine leiomyoma (Heim et al., 1988; Mark et al., 1988; Turc-Carel et al., 1988).

The identification of specific cytogenetic aberrations enabled meaningful clinical–cytogenetic association studies, the most important of which were the International Workshops on Chromosomes in Leukemia established in the late 1970s. The workshops provided an arena for a fruitful and at the time unique collaboration among cytogeneticists, clinicians, and pathologists who shared their data and insights in order to find diagnostically and prognostically interesting associations between cytogenetic aberrations and clinical characteristics in various hematologic disorders. The results obtained by this collaborative study group

over a 10-year period showed that cytogenetics could subdivide phenotypically identical leukemias and lymphomas into distinct subgroups on the basis of specific abnormalities and that this classification had important clinical implications. For example, the workshop collaborators demonstrated that the diagnostic karyotype in childhood acute lymphoblastic leukemia was of greater prognostic importance than any hitherto known risk factor, such as patient age, white blood cell count, or immunophenotype (Bloomfield et al., 1986). The studies performed by the Workshops on well-characterized patient materials from different parts of the world were thus instrumental in consolidating cytogenetics as clinically well-nigh indispensable in hematology. A similar collaborative study group dedicated to the genetic analysis of mesenchymal tumors—the Chromosomes and Morphology (CHAMP) study group—was formed a decade later and has identified several important clinical–cytogenetic associations among different bone and soft tissue tumors (e.g., Mertens et al., 1998).

Technological advances at the same time made it possible to supplement cytogenetic investigations by molecular genetic studies of the same tumor types. Analyses in the early 1980s of the specific translocations in MPC, BL, and CML proved particularly pivotal for our understanding of how chromosome aberrations contribute to neoplastic transformation not only in these specific disorders but also generally (Mitelman et al., 2007). The picture to emerge was that reciprocal translocations exert their effects by one of two main alternative mechanisms: deregulation, usually resulting in overexpression, of a seemingly normal gene in one of the breakpoints (the BL scenario) or the creation of a hybrid, chimeric gene through fusion of parts of two genes, one in each breakpoint (the CML scenario). Deregulation of an oncogene by juxtaposition to a constitutively active gene region was predicted by Klein already in 1981, and the principle was soon demonstrated in MPC (Adams et al., 1982; Harris et al., 1982; Kirsch et al., 1982) and human BL (Dalla Favera et al, 1982; Taub et al., 1982; Croce et al., 1983; Erikson et al., 1983). The breakpoints of the characteristic translocations in mice and humans were found to be located within or close to the *MYC* oncogene and one of the immunoglobulin heavy- or light-chain genes (*IGH*, *IGK*, or *IGL*). As a consequence of the translocations, the entire coding part of *MYC* is juxtaposed to one of the immunoglobulin genes, resulting in deregulation of *MYC* because the gene is now driven by regulatory elements of the immunoglobulin genes. The alternative mechanism—the creation of a fusion gene—was documented at the same time in CML with the demonstration that the Ph chromosome, that is, the der(22)t(9;22)(q34;q11), contains a fusion in which the 3′ part of the *ABL* oncogene from 9q34 has become juxtaposed with the 5′ part of a gene from 22q11 called the *BCR* gene, resulting in the creation of an in-frame BCR–ABL fusion transcript (de Klein et al., 1982; Heisterkamp et al., 1983; Groffen et al., 1984; Shtivelman et al., 1985).

These and similar molecular insights into how cancer-specific chromosomal abnormalities act pathogenetically sparked an enormous interest in cytogenetics as a powerful means to pinpoint the locations of genes important in tumorigenesis (Heim and Mitelman, 1987). An impressive amount of information has been accumulated through these efforts. More than 65 000 neoplasms with at least one clonal cytogenetic change have been identified, and more than 700 gene fusions have been found by genomic characterization of breakpoints in cytogenetically identified aberrations in various leukemias, lymphomas, and solid tumors (Mitelman et al., 2015). We now know that practically all acquired balanced rearrangements lead to in principle the same consequences as the ones originally elucidated in BL and CML, that is, deregulation of a seemingly normal gene or the creation of a hybrid gene. In addition to oncogene activation via translocations and other balanced rearrangements (inversions, insertions), gene fusions may also be produced by unbalanced changes such as deletions leading to fusion of genes in the deletion edges.

The advent of molecular genetics in the 1980s and the development of a range of powerful molecular cytogenetic technologies during the last three decades, such as fluorescence *in situ* hybridization (FISH), multicolor FISH, comparative genomic hybridization (CGH), various array-based genotyping technologies, and DNA and RNA sequencing (Lander, 2011; Ozsolak and Milos, 2011;

Le Scouarnac and Gribble, 2012; Mwenifumbo and Marra, 2013; Mertens and Tayebwa, 2014), have dramatically widened our knowledge and understanding of the molecular mechanisms that are operative in neoplastic initiation and progression. The new techniques have enabled researchers to investigate tumor cells at the level of individual genes, even at the level of single base pairs, and the molecular consequences of an ever increasing number of cancer-associated genomic aberrations have thus been laid bare (Vogelstein et al., 2013).

It is obvious that the cross-fertilization between cytogenetics and molecular genetics has led to conceptually new advances and insights into the fundamental cell biology mechanisms that are disrupted when neoplastic transformation occurs. At the same time, the clinical usefulness of cytogenetic abnormalities as diagnostic and prognostic aids in cancer medicine has been increasingly appreciated. The ultimate goal is to arrive at specific therapies individualized to counter those molecular mechanisms that have gone awry in each patient's cancerous disease. The development of imatinib (Druker, 2008) as a therapeutic agent for CML—the first example of a targeted therapy against a specific fusion gene in cancer—is a wonderful example of how progress in cytogenetics and molecular biology has led to a qualitatively new treatment approach: the discovery of the Ph chromosome, the finding that the Ph chromosome results from a reciprocal translocation, the identification of the two genes in the breakpoints of the translocation, and the subsequent characterization of the fusion gene and its protein product. Similar targeted therapies are presently being developed against a number of fusion genes, and some have already turned out to be successful, for example, crizotinib targeting the *EML4–ALK* fusion gene generated by an inversion on the short arm of chromosome 2 in a subset of patients with non-small cell lung cancer (Shaw and Engelman, 2013). While it took 40 years from the discovery of the Ph chromosome to the development of imatinib, it only took a few years from the description of the *EML4–ALK* fusion in lung cancer to the development of crizotinib. We are convinced that many similar success stories are unfolding as we write; cancer genetic research helps obtain more effective and less toxic treatments for malignant diseases. Thus, in the 100 years since Boveri first postulated that chromosome change may initiate the carcinogenic process, cancer cytogenetics has come of age. It is no longer a purely descriptive discipline but one that attempts to synthesize information from several investigative approaches. Cancer cytogenetics has become both a central methodology in basic cancer research and an important clinical tool in oncology.

References

Adams JM, Gerondakis S, Webb E, Mitchell J, Bernard O, Cory S (1982): Transcriptionally active DNA region that rearranges frequently in murine lymphoid tumors. *Proc Natl Acad Sci USA* 22:6966–6970.

Atkin NB, Baker MC (1982): Specific chromosome change, i(12p), in testicular tumors? *Lancet* 2:1349.

Aurias A, Rimbaut C, Buffe D, Dubousset J, Mazabraud A (1983): Chromosomal translocations in Ewing's sarcoma. *N Engl J Med* 309:496–497.

Autio K, Turunen O, Penttila O, Eramaa E, de la Chapelle A, Schröder J (1979): Human chronic lymphocytic leukemia: Karyotypes in different lymphocyte populations. *Cancer Genet Cytogenet* 1:147–155.

Balaban G, Gilbert F, Nicholas W, Meadows AT, Shields J (1982): Abnormalities of chromosome #13 in retinoblastomas from individuals with normal constitutional karyotypes. *Cancer Genet Cytogenet* 6:213–221.

Berger R (1975): Translocation t(11;20) et polyglobulie primitive. *Nouv Presse Med* 4:1972.

Berger R, Bernheim A, Brouet JC, Daniel MT, Flandrin G (1979a): t(8;14) translocation in a Burkitt's type of lymphoblastic leukaemia (L3). *Br J Haematol* 43:87–90.

Berger R, Bernheim A, Weh H-J, Flandrin G, Daniel MT, Brouet J-C, et al. (1979b): A new translocation in Burkitt's tumor cells. *Hum Genet* 53:111–112.

van den Berghe H, Cassiman JJ, David G, Fryns JP, Michaux JL, Sokal G (1974): Distinct haematological disorder with deletion of long arm of no. 5 chromosome. *Nature* 251:437–438.

van den Berghe H, Parloir C, Gosseye S, Englebienne V, Cornu G, Sokal G (1979): Variant translocation in Burkitt lymphoma. *Cancer Genet Cytogenet* 1:9–14.

Bloomfield CD, Goldman AI, Alimena G, Berger R, Borgström GH, Brandt L, et al. (1986): Chromosomal abnormalities identify high-risk and low-risk patients with acute lymphoblastic leukemia. *Blood* 67:415–420.

Boghosian L, Dal Cin P, Sandberg AA (1988): An interstitial deletion of chromosome 7 may characterize a subgroup of uterine leiomyoma. *Cancer Genet Cytogenet* 34:207–208.

Boveri T (1914): *Zur Frage der Entstehung maligner Tumoren*. Jena: Gustav Fischer.

Brodeur GM, Sekhon GS, Goldstein MN (1977): Chromosomal aberrations in human neuroblastomas. *Cancer* 40:2256–2263.

Bullerdiek J, Haubrich J, Meyer K, Bartnitzke S (1988): Translocation t(11;19)(q21;p13.1) as the sole chromosome abnormality in a cystadenolymphoma (Warthin's tumor) of the parotid gland. *Cancer Genet Cytogenet* 35:129–132.

Caspersson T, Zech L, Johansson C (1970a): Differential binding of alkylating fluorochromes in human chromosomes. *Exp Cell Res* 60:315–319.

Caspersson T, Gahrton G, Lindsten J, Zech L (1970b): Identification of the Philadelphia chromosome as a number 22 by quinacrine mustard fluorescence analysis. *Exp Cell Res* 63:238–240.

de la Chapelle A, Schröder J, Vuopio P (1972): 8-Trisomy in the bone marrow. Report of two cases. *Clin Genet* 3:470–476.

Croce CM, Thierfelder W, Erikson J, Nishikura K, Finan J, Lenoir GM, et al. (1983): Transcriptional activation of an unrearranged and untranslocated c-myc oncogene by translocation of a C lambda locus in Burkitt. *Proc Natl Acad Sci USA* 80:6922–6926.

Dalla-Favera R, Bregni M, Erikson J, Patterson D, Gallo RC, Croce CM (1982): Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. *Proc Natl Acad Sci USA* 79:7824–7827.

Davidson WM, Knight LA (1973): Acquired trisomy 9. *Lancet* 1:1510.

Druker BJ (2008): Translation of the Philadelphia chromosome into therapy for CML. *Blood* 112: 4808–4817.

Erikson J, Nishikura K, ar-Rushdi A, Finan J, Emanuel B, Lenoir G, et al. (1983): Translocation of an immunoglobulin kappa locus to a region 3′ of an unrearranged c-myc oncogene enhances c-myc transcription. *Proc Natl Acad Sci USA* 80:7581–7585.

Fukuhara S, Rowley JD, Variakojis D, Golomb HM (1979): Chromosome abnormalities in poorly differentiated lymphocytic lymphoma. *Cancer Res* 39:3119–3128.

Golomb HM, Vardiman JW, Rowley JD, Testa JR, Mintz U (1978): Correlation of clinical findings with quinacrine-banded chromosomes in 90 adults with acute nonlymphocytic leukemia. An eight-year study (1970–1977). *N Engl J Med* 299:613–619.

Griffin CA, Hawkins AL, Packer RJ, Rorke LB, Emanuel BS (1988): Chromosome abnormalities in pediatric brain tumors. *Cancer Res* 48:175–180.

Groffen J, Stephenson JR, Heisterkamp N, de Klein A, Bartram CR, Grosveld G (1984): Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. *Cell* 36:93–99.

von Hansemann D (1890): Ueber asymmetrische Zelltheilung in Epithelkrebsen und deren biologische Bedeutung. *Virchows Arch Anat* 119:299–326.

Harris LJ, Lang RB, Marcu KB (1982): Non-immunoglobulin-associated DNA rearrangements in mouse plasmacytomas. *Proc Natl Acad Sci USA* 79:4175–4179.

Hauschka TS (1953): Cell population studies on mouse ascites tumors. *Ann N Y Acad Sci* 16:64–73.

Heim S, Mitelman F (1987): *Cancer Cytogenetics*. New York: Alan R. Liss, Inc.

Heim S, Mandahl N, Kristoffersson U, Mitelman F, Rööser B, Rydholm A, Willén H (1986): Reciprocal translocation t(3;12)(q27;q13) in lipoma. *Cancer Genet Cytogenet* 23:301–304.

Heim S, Mandahl N, Kristoffersson U, Mitelman F, Rööser B, Rydholm A, Willén H (1987): Marker ring chromosome—a new cytogenetic abnormality characterizing lipogenic tumors? *Cancer Genet Cytogenet* 24:319–326.

Heim S, Nilbert M, Vanni R, Floderus U-M, Mandahl N, Liedgren S, Lecca U, Mitelman F (1988): A specific translocation, t(12;14)(q14–15;q23–24), characterizes a subgroup of uterine leiomyomas. *Cancer Genet Cytogenet* 32:13–17.

Heisterkamp N, Stephenson JR, Groffen J, Hansen PF, de Klein A, Bartram CR, Grosveld G (1983): Localization of the c-ab1 oncogene adjacent to a translocation break point in chronic myelocytic leukaemia. *Nature* 306:239–242.

Hinrichs SH, Jaramillo MA, Gumerlock PH, Gardner MB, Lewis JP, Freeman AE (1985): Myxoid chondrosarcoma with a translocation involving chromosomes 9 and 22. *Cancer Genet Cytogenet* 14:219–226.

Hsu TC (1979): *Human and Mammalian Cytogenetics*. An Historical Perspective. New York: Springer Verlag.

Hungerford DA, Nowell PC (1962): Chromosome studies in human leukemia III. Acute granulocytic leukemia. *J Natl Cancer Inst* 29:545–565.

de Jong B, Molenaar IM, Leeuw JA, Idenberg VJS, Oosterhuis JW (1986): Cytogenetics of a renal adenocarcinoma in a 2-year-old child. *Cancer Genet Cytogenet* 21:165–169.

Kamada N, Okada K, Ito T, Nakatsui T, Uchino H (1968): Chromosomes 21–22 and neutrophil alkaline phosphatase in leukaemia. *Lancet* 1: 364.

Kaneko Y, Kondo K, Rowley JD, Moohr JW, Maurer HS (1983): Further chromosome studies on Wilms' tumor cells of patients without aniridia. *Cancer Genet Cytogenet* 10:191–197.

Kay HEM, Lawler SD, Millard RE (1966): The chromosomes in polycythemia vera. *Br J Haematol* 12: 507–527.

Kirsch IR, Morton CC, Nakahara K, Leder P (1982): Human immunoglobulin heavy chain genes map to a region of translocations in malignant B lymphocytes. *Science* 216:301–303.

Klein G (1981): The role of gene dosage and genetic transpositions in carcinogenesis. *Nature* 294:313–318.

de Klein A, van Kessel AG, Grosveld G, Bartram CR, Hagemeijer A, Bootsma D, et al. (1982): A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia. *Nature* 300:765–767.

Koller PC (1972): *The Role of Chromosomes in Cancer Biology. Recent Results in Cancer Research*. Vol 38. Berlin: Springer Verlag.

Kovacs G, Szücs S, de Riese W, Baumgärtel H (1987): Specific chromosome aberration in human renal cell carcinoma. *Int J Cancer* 40:171–178.

Kusnetsova LE, Prigogina EL, Pogosianz HE, Belkina BM (1982): Similar chromosomal abnormalities in several retinoblastomas. *Hum Genet* 61:201–204.

Lander ES (2011): Initial impact of the sequencing of the human genome. *Nature* 470:187–197.

Le Scouarnac S, Gribble SM (2012): Characterising chromosome rearrangements: Recent technical advances in molecular cytogenetics. *Heredity* 108:75–85.

Levan A (1956): Chromosomal studies on some human tumors and tissues of normal origin, grown in vivo and in vitro at the Sloan-Kettering Institute. *Cancer* 9:648–663.

Levan A (1966): Non-random representation of chromosome types in human tumor stemlines. *Hereditas* 55:28–38.

Levan A (1967): Some current problems of cancer cytogenetics. *Hereditas* 57:343–355.

Limon J, Turc-Carel C, Dal Cin P, Rao U, Sandberg AA (1986a): Recurrent chromosome translocations in liposarcoma. *Cancer Genet Cytogenet* 22:93–94.

Limon J, Dal Cin P, Sandberg AA (1986b): Translocations involving the X chromosome in solid tumors: Presentation of two sarcomas with t(X;18)(q13;p11). *Cancer Genet Cytogenet* 23:87–91.

Makino S (1956): Further evidence favoring the concept of the stem cell in ascites tumors of rats. *Ann N Y Acad Sci* 63:818–830.

Mandahl N, Heim S, Johansson B, Bennet K, Mertens F, Olsson G, et al. (1987): Lipomas have characteristic structural chromosomal rearrangements of 12q13–q14. *Int J Cancer* 39:685–688.

Mandahl N, Heim S, Rydholm A, Willén H, Mitelman F (1989): Nonrandom numerical chromosome aberrations (+8, +11, +17, +20) in infantile fibrosarcoma. *Cancer Genet Cytogenet* 40:137–139.

Manolov G, Manolova Y (1972): Marker band in one chromosome 14 from Burkitt lymphomas. *Nature* 237:33–34.

Mark J, Levan G, Mitelman F (1972): Identification by fluorescence of the G chromosome lost in human meningomas. *Hereditas* 71:163–168.

Mark J, Dahlenfors R, Ekedahl C, Stenman G (1980): The mixed salivary gland tumor—a normally benign human neoplasm frequently showing specific chromosomal abnormalities. *Cancer Genet Cytogenet* 2:231–241.

Mark J, Havel G, Grepp C, Dahlenfors R, Wedell B (1988): Cytogenetical observations in human benign uterine leiomyomas. *Anticancer Res* 8:621–626.

Mertens F, Tayebwa J (2014): Evolving techniques for gene fusion detection in soft tissue tumours. *Histopathology* 64:151–162.

Mertens F, Fletcher CDM, Dal Cin P, De Wever I, Mandahl N, Mitelman F, et al. (1998): Cytogenetic analysis of 46 pleomorphic soft tissue sarcomas and correlation with morphologic and clinical features: A report of the CHAMP Study Group. *Genes Chromosomes Cancer* 22:16–25.

Mitelman F (1974): The Rous sarcoma virus story: Cytogenetics of tumors induced by RSV. In German J (ed): *Chromosomes and Cancer*. New York: John Wiley & Sons, pp. 675–693.

Mitelman F, Brandt L (1974): Chromosome banding pattern in acute myeloid leukemia. *Scand J Haematol* 13:321–330.

Mitelman F, Brandt L, Levan G (1973): Identification of isochromosome 17 in acute myeloid leukaemia. *Lancet* 2:972.

Mitelman F, Brandt L, Nilsson PG (1978): Relation among occupational exposure to potential mutagenic/carcinogenic agents, clinical findings, and bone marrow chromosomes in acute nonlymphocytic leukemia. *Blood* 52:1229–1237.

Mitelman F, Andersson-Anvret M, Brandt L, Catovsky D, Klein G, Manolov G, et al. (1979): Reciprocal 8;14 translocation in EBV-negative B-cell acute lymphocytic leukemia with Burkitt-type cells. *Int J Cancer* 24:27–33.

Mitelman F, Johansson B, Mertens F (2007): The impact of translocations and gene fusions on cancer causation. *Nat Rev Cancer* 7:233–245.

Mitelman F, Johansson B, Mertens F (Eds.) (2015): Mitelman Database of Chromosome Aberrations and Gene Fusions in Cancer. http://cgap.nci.nih.gov/Chromosomes/Mitelman.

Miyoshi I, Hiraki S, Kimura I, Miyamoto K, Sato J (1979): 2/8 translocation in a Japanese Burkitt's lymphoma. *Experientia* 35:742–743.

Moorhead PS, Nowell PC, Mellman WJ, Battips DM, Hungerford DA (1960): Chromosome preparations of leukocytes cultured from human peripheral blood. *Exp Cell Res* 20:613–616.

Mwenifumbo JC, Marra MA (2013): Cancer genome-sequencing study design. *Nat Rev Genet* 14:321–332.

Nowell PC (1960): Phytohemagglutinin: An initiator of mitosis in cultures of normal human leukocytes. *Cancer Res* 20:462–466.

Nowell PC, Hungerford DA (1960): A minute chromosome in human chronic granulocytic leukemia. *Science* 132:1497.

Ohno S, Babonits M, Wiener F, Spira J, Klein G, Potter M (1979): Nonrandom chromosome changes involving the Ig gene-carrying chromosomes 12 and 6 in pristane-induced mouse plasmacytomas. *Cell* 18:1001–1007.

Oshimura M, Freeman AI, Sandberg AA (1977): Chromosomes and causation of human cancer and leukemia. XXVI. Banding studies in acute lymphoblastic leukemia (ALL). *Cancer* 40:1161–1172.

Ozsolak F, Milos PM (2011): RNA sequencing: Advances, challenges and opportunities. *Nat Rev Genet* 12:87–98.

Pejovic T, Heim S, Mandahl N, Elmfors B, Flodérus U-M, Furgyik S, et al. (1989): Consistent occurrence of a 19p + marker chromosome and loss of 11p material

in ovarian seropapillary cystadenocarcinomas. *Genes Chromosomes Cancer* 1:167–171.

Petit P, Alexander M, Fondu P (1973): Monosomy 7 in erythroleukaemia. *Lancet* 2:1326–1327.

Reeves BR, Lobb DS, Lawler SD (1972): Identity of the abnormal F-group chromosome associated with polycythaemia vera. *Humangenetik* 14:159–161.

Rowley JD (1973a): Identification of a translocation with quinacrine fluorescence in a patient with acute leukemia. *Ann Genet* 16:109–112.

Rowley JD (1973b): A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. *Nature* 243:290–293.

Rowley JD (1973c): Deletions of chromosome 7 in haematological disorders. *Lancet* 2:1385–1386.

Rowley JD (1973d): Acquired trisomy 9. *Lancet* 2:390.

Rowley JD, Potter D (1976): Chromosomal banding patterns in acute nonlymphocytic leukemia. *Blood* 47: 705–721.

Rowley JD, Golomb HM, Dougherty C (1977): 15/17 translocation, a consistent chromosomal change in acute promyelocytic leukaemia. *Lancet* 1:549–550.

Rutten FJ, Hustinx TW, Scheres MJ, Wagener DJ (1973): Acquired trisomy 9. *Lancet* 2:455.

Sait SNJ, Dal Cin P, Sandberg AA, Leong S, Karakousis C, Rao U, et al. (1989): Involvement of 6p in benign lipomas. A new cytogenetic entity? *Cancer Genet Cytogenet* 37:281–283.

Sandberg AA (1980): *The Chromosomes in Human Cancer and Leukemia*. New York: Elsevier/North-Holland.

Seidal T, Mark J, Hagmar B, Angervall L (1982): Alveolar rhabdomyosarcoma: A cytogenetic and correlated cytological and histological study. *APMIS* 90:345–354.

Shaw AT, Engelman JA (2013): ALK in lung cancer: Past, present, and future. *J Clin Oncol* 31:1105–1111.

Shtivelman E, Lifshitz B, Gale RP, Canaani E (1985): Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. *Nature* 315:550–554.

Speleman F, Dal Cin P, De Potter K, Laureys G, Roels HJ, Leroy J, et al. (1989): Cytogenetic investigation of a case of congenital fibrosarcoma. *Cancer Genet Cytogenet* 39:21–24.

van Steenis H (1966): Chromosomes and cancer. *Nature* 209:819–821.

Stenman G, Mark J (1983): Specificity of the involvement of chromosomes 8 and 12 in human mixed salivary-gland tumours. *J Oral Pathol* 12:446–457.

Stenman G, Sandros J, Dahlenfors R, Juberg-Ode M, Mark J (1986): 6q- and loss of the Y chromosome – two common deviations in malignant human salivary gland tumors. *Cancer Genet Cytogenet* 22:283–293.

Taub R, Kirsch I, Morton C, Lenoir G, Swan D, Tronick S, et al. (1982): Translocation of the c-myc gene into the immunoglobulin heavy chain locus in human Burkitt lymphoma and murine plasmacytoma cells. *Proc Natl Acad Sci USA* 79:7837–7841.

Tjio JH, Levan A (1956): The chromosome number of man. *Hereditas* 42:1–6.

Turc-Carel C, Philip I, Berger M-P, Philip T, Lenoir GM (1983): Chromosomal translocations in Ewing's sarcoma. *N Engl J Med* 309:497–498.

Turc-Carel C, Dal Cin P, Rao U, Karakousis C, Sandberg AA (1986): Cytogenetic studies of adipose tissue tumors. I. A benign lipoma with reciprocal translocation t(3;12)(q28;q14). *Cancer Genet Cytogenet* 23:283–289.

Turc-Carel C, Dal Cin P, Boghosian L, Terk-Zakarian J, Sandberg AA (1988): Consistent breakpoints in region 14q22–q24 in uterine leiomyoma. *Cancer Genet Cytogenet* 32:25–31.

Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW (2013): Cancer genome landscapes. *Science* 339:1546–1558.

Whang-Peng J, Bunn PA, Kao-Shan CS, Lee EC, Carney DN, Gazdar A, Minna JO (1982) A nonrandom chromosomal abnormality, del 3p(14–23),in human small lung cancer. *Cancer Genet Cytogenet* 6:119–134.

Winge Ö (1930): Zytologische Untersuchungen über die Natur maligner Tumoren. II. Teerkarzinome bei Mäusen. *Z Zellforsch Mikrosk Anat* 10:683–735.

Zang KD, Singer H (1967): Chromosomal constitution of meningiomas. *Nature* 216: 84–85.

Zankl K, Zang KD (1972): Cytological and cytogenetical studies on brain tumors. 4. Identification of the missing G chromosome in human meningiomas as no. 22 by fluorescence technique. *Humangenetik* 14:167–169.

Zech L, Haglund U, Nilsson K, Klein G (1976): Characteristic chromosomal abnormalities in biopsies and lymphoid-cell lines from patients with Burkitt and non-Burkitt lymphomas. *Int J Cancer* 17:47–56.

2

CHAPTER 2

Cytogenetic methods

David Gisselsson
Department of Clinical Genetics, University of Lund, Lund, Sweden

The human chromosome complement consists of 22 pairs of autosomes and one pair of sex chromosomes, XX in females and XY in males. The autosomes are numbered after their relative lengths, with the exception of chromosomes 21 and 22. For stable function of a chromosome, a *centromere* somewhere along its length and a *telomere* at each terminus are required. The centromere is associated with the kinetochore protein complex necessary for anchoring of the spindle fibers and for separation of sister chromatids at the metaphase–anaphase transition. Centromeric regions contain large areas of repetitive DNA sequences, some of which contribute to the segments of *constitutive heterochromatin* found around the centromeres of all chromosomes, though most prominently in 1, 9, 16, and Y. Another type of repetitive DNA element is located at the telomeres. These tandemly repeated TTAGGG hexamer units maintain the structural integrity of chromosome termini and ensure complete replication of the most terminal nonrepetitive sequences.

Since the correct chromosome number of man was reported more than half a century ago (Tjio and Levan, 1956), our possibilities to analyze the human chromosome complement have improved steadily. This chapter is an attempt to outline the methods currently employed in cancer cytogenetics, spanning from chromosome banding to array- and sequencing-based techniques. Cytogenetic methods have traditionally been based on microscopic examination of individual cells, and it can be argued that next-generation sequencing (NGS) and genomic arrays are not cytogenetics. However, also these techniques can be used to obtain significant data on overall genome architecture in cells and could therefore with all rights be considered high-resolution cytogenetics. The practical details and protocols of the specific methods will only be touched upon, and the reader is referred to the individual articles cited in this and later chapters for more detailed information.

Sampling for cytogenetic analysis

A correct sampling procedure is the basis for correct scientific and diagnostic conclusions. A first issue to consider is whether the sample is sufficient for the planned analyses. Chromosome preparation requires live cells, whereas *in situ* hybridization at least requires intact nuclei, and genome arrays as well as sequencing rely on DNA that has not been extensively degraded. Another issue to consider is whether the sample is representative of the lesion to be investigated. Cytogeneticists rarely know precisely which cells they study. Exceptions to this are when *in situ* hybridization is combined with immunohistochemical staining of intact cells or when DNA is extracted for analysis

Cancer Cytogenetics: Chromosomal and Molecular Genetic Aberrations of Tumor Cells, Fourth Edition.
Edited by Sverre Heim and Felix Mitelman.
© 2015 John Wiley & Sons, Ltd. Published 2015 by John Wiley & Sons, Ltd.

from fixed microdissected solid tumor components, from reviewed cryosections, or from flow-sorted cells. When analysis is performed on cultured cells, it is further important to consider whether the results are representative of the *in vivo* situation. Two main types of heterogeneity can be expected at cytogenetic analysis of a tumor sample: that between neoplastic and nonneoplastic cells and that among various neoplastic cells (Pandis et al., 1994; Lindgren et al., 2011). *In vitro* overgrowth of normal cells or of neoplastic subclones can bias the cytogenetic results. This is a major reason why the use of established cell lines can have serious disadvantages. Pronounced selection may occur among clones that were present already *in vivo*, and chromosomal aberrations that emerge *in vitro* may be mistaken for *in vivo* changes (Gisselsson et al., 2010). Finally, many human tumor cell lines are contaminated by other human or animal cells (Lacroix, 2008). Direct preparations or short-term cultures are therefore usually preferred for chromosome banding analysis.

Chromosome banding

Chromosomes are typically studied at the metaphase stage of the cell cycle when the chromatin is highly condensed and the chromosome morphology is well defined. In most banding methods, individual chromosomes are identified by their relative size, the position of the centromere, and the patterns of transverse striations. Based on this, the short (p) and long (q) chromosome arms are divided into different morphological *regions*, which in turn can be subdivided into *bands* and *subbands*, their number depending on the resolution of the preparation technique. The first of these methods to be invented was *Q-banding* (Caspersson et al., 1970), for which metaphase chromosomes are stained with quinacrine mustard and examined through a fluorescence microscope. A partial explanation of the Q-banding pattern is that quinacrine stains AT-rich sequences brighter than GC-rich sequences (Weisblum and De Haseth, 1972). Most striking are the very bright Q-bands containing highly AT-rich satellite DNA, particularly in the distal part of the Y chromosome. *G-banding* (Figure 2.1A) is obtained when the chromosomes are pretreated with a salt solution or a proteolytic enzyme before staining with Giemsa or equivalent stains. G-banding yields approximately the same information as Q-banding; bands that fluoresce intensely by Q-banding stain darkly by G-banding. *R-banding* is obtained by pretreatment with hot alkali and subsequent staining with Giemsa or acridine orange (Dutrillaux and Lejeune, 1971). As the name indicates, R-banding yields a pattern that is the reverse of that obtained by G-and Q-banding. However, since R-banding stains the chromosome ends intensely, this technique may be preferable to G- or Q-banding when it comes to detecting terminal chromosome rearrangements.

G-banding and other whole-genome banding methods are still used in routine cytogenetic diagnostic investigations and in research. In fact, chromosome banding remains the only truly low-cost genome screening technique allowing the identification of balanced as well as unbalanced genomic rearrangements in single cells (Table 2.1). Besides these whole-genome banding methods, there are several sequence-specific techniques, of which *C-banding* is most commonly used. This is produced by denaturing the chromosomes prior to Giemsa staining (Sumner, 1972). The method labels the constitutive heterochromatin, thus especially demarcating the variable heterochromatic blocks on chromosomes 1, 9, 16, and Y.

In situ hybridization

In situ hybridization techniques are based on the inherent organization of DNA into two antiparallel complementary strands. After denaturation of target DNA in metaphase spreads or interphase nuclei, single-stranded DNA probes are allowed to form hybrid double-stranded complexes with their complementary genomic sequences. Before hybridization, probes can be labeled by fluorophores to allow direct detection by fluorescence microscopy (Pinkel et al., 1986; Cremer et al., 1988). This fluorescence *in situ* hybridization (FISH) strategy allows simultaneous detection of several genomic sequence targets as fluorophores of different wavelengths can be combined in the same hybridization experiment and concurrently detected (Figure 2.1B–D). However, probes can also be labeled with nonfluorescent haptens, allowing secondary detection by enzymatic methods analogous to those used in immunohistochemistry. This chromogenic *in situ* hybridization (CISH) technique avoids the problem of tissue autofluorescence and can therefore be advantageous for direct analysis of fixed tissue sections (Tanner et al., 2000; Hsi et al., 2002).



Figure 2.1 Examples of how different cytogenetic techniques can be used to delineate chromosome aberrations at different levels of resolution. A supernumerary ring chromosome (arrow) is identified by G-banding (A) in a soft tissue tumor and shown by multicolor FISH paint (B) to contain sequences from chromosomes 9 (arrowhead) and 12 (arrow). Whole-chromosome painting (C) of chromosomes 9 (red) and 12 (green) corroborates these findings, and multicolor chromosome 12 banding with single-copy probes (D) shows that sequences from the *MDM2* (yellow) and *CDK4* (violet) genes in 12q13–15 are amplified in the rings. Further analysis with SNP array (E) defines the boundaries of the 12q-amplified segments, which include *CDK4* and *MDM2*. The *y*-axis of the upper panel corresponds to relative gene copy number (log2 ratio). The *y*-axis of the lower panel shows the mirrored B-allele frequency (mBAF), which is shifted toward homozygosity (mBAF = 1) in the amplified regions. Array images are courtesy of Dr. K. Hansén Nord.